CASP3 and breast cancer: Our results demonstrated that NKExos loaded with siBCL-2 exhibited a promising killing ability in ER+ breast cancer and led to induction of Annexin V, Caspase 3/7, and Caspase 9 over time, which clearly demonstrates the efficacy of siRNA NKExos for treatment of breast cancer.